Clot risk far lower from vaccines than virus: UK study

Researchers examined data on 29 million people in England, where concerns have risen after the vaccine-related death of a BBC presenter.

The risk of rare blood clotting after receiving first doses of AstraZeneca or Pfizer COVID-19 jabs is far lower than from the virus, a large-scale study by researchers from the University of Oxford found on Friday. Fears over rare cases of clotting conditions have prompted some countries to rule out or limit rollout of the Oxford-developed AstraZeneca jab, with the United Kingdom recommending that healthy people under 40 get alternative vaccines. The study published in the BMJ medical journal examined data on 29 million people in England first vaccinated between December and April.